The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Hims & Hers Health is set to have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to bar the game’s host, Fox, from broadcasting it. Why? Experts, advocates and politicians are saying that the 60-second spot — which deems obesity “America’s deadliest epidemic,